|
carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamide }} Ibodutant is a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. , it is undergoing a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe(the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study in women is ongoing. ==See also== * GR-159,897 * Nepadutant * Saredutant 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Ibodutant」の詳細全文を読む スポンサード リンク
|